For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit:
www.BMSStudyConnect.com
Inclusion Criteria:
- Participants with histologically or cytologically confirmed locally advanced
unresectable, metastatic, or recurrent select solid tumor
- Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC),
Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC),
Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal
adenocarcinoma (PDAC)
- Resistant/refractory to or intolerant of existing standard therapies known to provide
clinical benefit
- Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1
(RECIST v 1.1)
- Disease amenable to serial biopsy
Exclusion Criteria:
- Uncontrolled or significant cardiovascular disease
- Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome
- Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose
aspirin, which is permitted)
Other protocol-defined inclusion/exclusion criteria apply
